ASCO 2024 Archives - Medical Conferences

Home > Oncology > ASCO 2024

American Society of Clinical Oncology
31 May–04 June 2024
Chicago, IL, USA

Letter from the Editor

Editor

Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Luxembourg

Meet the Trialist: Prof. Giuseppe Curigliano on DESTINY-Breast06

Expert

Prof. Giuseppe Curigliano, University of Milan, Italy

Gastrointestinal: Colorectal Cancer

No survival benefit of tumour debulking for patients with multi-organ metastatic CRC

Presented By

Dr Elske Gootjes, Radboudumc, the Netherlands

Thermal ablation of small-size colorectal liver metastases is non-inferior to resection

Presented By

Prof. Martijn Meijerink, Amsterdam UMC, the Netherlands

Benefit of first-line nivolumab/ipilimumab in MSI-H/dMMR metastatic CRC

Presented By

Prof. Heinz-Josef Lenz, University of Southern California Norris Comprehensive Cancer Center, CA, USA

Neoadjuvant checkpoint blockade in MSI-H/dMMR CRC

CodeBreaK 300: Promising survival trends in KRAS G12C-mutated mCRC

Presented By

Prof. Marwan Fakih, City of Hope Comprehensive Cancer Center, CA, USA

Gastrointestinal: Upper GI Cancer

FLOT outperforms CROSS in resectable oesophageal cancer

Presented By

Prof. Jens Höppner, University of Bielefeld, Germany

Nivolumab/ipilimumab combination outperforms TKIs in unresectable HCC

Presented By

Dr Peter Galle, Universitätsmedizin Mainz, Germany

No advantage of neoadjuvant radiochemotherapy over neoadjuvant chemotherapy in borderline resectable pancreatic cancer

Presented By

Dr Masafumi Ikeda, National Cancer Center Hospital East, Japan

Breast Cancer

Benefit of abemaciclib plus fulvestrant after progression on a CDK4/6 inhibitor

Presented By

Prof. Kevin Kalinsky, Emory School of Medicine, GA, USA

ctDNA is prognostic of worse outcomes for CDK4/6 therapy

Presented By

Prof. Sherene Loi, Peter MacCallum Cancer Centre, Australia

Adjuvant avelumab significantly improves survival in early TNBC

Presented By

Prof. Pierfranco Conte, University of Padova, Italy

High pCR rate after neoadjuvant Dato-DXd plus durvalumab therapy

Presented By

Dr Jane Meisel, Emory School of Medicine, GA, USA & Dr Rebecca Shatsky, University of California San Diego, CA, USA

Lung Cancer

Osimertinib significantly improves PFS in patients with unresectable stage III EGFR-mutated NSCLC

Presented By

Prof. Suresh Ramalingam, Emory School of Medicine, GA, USA

First-line lorlatinib provides unprecedented improvement for patients with advanced ALK-positive NSCLC

Presented By

Prof. Benjamin Solomon, Peter MacCallum Cancer Centre, Australia

Comparable benefit of video- and in-person-delivered palliative care

Presented By

Dr Joseph Greer, Harvard Medical School, MA, USA

Consolidation with durvalumab improves survival in LS-SCLC

Presented By

Dr David Spigel, Sarah Cannon Research Institute, TN, USA

Subcutaneous amivantamab non-inferior and more convenient than intravenous amivantamab

Presented By

Dr Natasha Leighl, Princess Margaret Cancer Centre, Canada

Melanoma

Highly significant event-free survival benefit with neoadjuvant nivolumab/ipilimumab in stage III melanoma

Presented By

Prof. Christian Blank, Antoni van Leeuwenhoek, the Netherlands

Neoadjuvant intralesional daromun improves relapse-free survival in stage III melanoma

Presented By

Prof. Axel Hauschild, Universitätsklinikum Schleswig-Holstein, Germany

Intratumoural tilsotolimod shows no benefit for advanced refractory melanoma

Presented By

Prof. Caroline Robert, Gustave Roussy, France

Genitourinary Cancer

Immune-enhancing nutrition does not affect complication rate of radical cystectomy

Presented By

Prof. Jill Hamilton-Reeves, University of Kansas Medical Center, KS, USA

Biomarkers for treatment of renal cell carcinoma

ctDNA changes as biomarker for pembrolizumab response in advanced urothelial carcinoma

Presented By

Prof. Thomas Powles, Barts Cancer Institute, UK

Highest efficacy of nivolumab/chemotherapy in lymph-node-only metastatic urothelial carcinoma

Presented By

Prof. Matthew Galsky, Tisch Cancer Institute, NY, USA

Genitourinary: Prostate Cancer

Metformin does not prevent progression of low-risk prostate cancer

Presented By

Dr Anthony Joshua, Princess Margaret Cancer Centre, Canada

Baseline ctDNA has both prognostic and predictive value in mCRPC

Presented By

Prof. Johann de Bono, Royal Marsden Hospital, UK

Oxybutynin significantly decreases frequency and severity of hot flashes in men on ADT

Presented By

Dr Brad Stish, Mayo Clinic, MN, USA

Gynaecological Cancer

Batiraxcept shows promise in high AXL-expressing, platinum-resistant ovarian cancer

Presented By

Dr Katherine Fuh, University of California San Francisco, CA, USA

No lymphadenectomy for advanced ovarian cancer without suspicious nodes

Presented By

Prof. Jean-Marc Classe, Nantes Université, France

SIENDO: Efficacy benefit of selinexor in TP53 wildtype endometrial cancer

Presented By

Dr Vicky Makker, Memorial Sloan Kettering Cancer Center, NY, USA

Novel regimen for HR-positive endometrial cancer on the way?

Presented By

Dr Angela Green, Memorial Sloan Kettering Cancer Center, NY, USA

Table of Contents

Featured articles

Gastrointestinal: Colorectal Cancer

Gastrointestinal: Upper GI Cancer

Breast Cancer

Lung Cancer

Melanoma

Genitourinary Cancer

Genitourinary: Prostate Cancer

Gynaecological Cancer